CiRC Biosciences
Private Company
Total funding raised: $5.5M
Overview
CiRC Biosciences is a private, early-stage biotech founded in 2021, headquartered in Cambridge, Massachusetts, with a listed address in Chicago, Illinois. The company is pioneering a cellular reprogramming platform to address degenerative diseases characterized by cell loss, such as those causing vision loss. Operating in the high-risk, high-reward space of regenerative medicine, CiRC is pre-clinical and pre-revenue, positioning itself to tackle significant unmet medical needs where traditional therapeutic targets are absent. The company's success hinges on validating its platform and advancing its initial programs into clinical development.
Technology Platform
Investigational cellular reprogramming platform designed to convert one mature cell type into another in vivo to replace cells lost in degenerative diseases.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
CiRC competes in the broad regenerative medicine and cell therapy space. Direct competitors include companies developing in vivo reprogramming approaches (e.g., Lineage Cell Therapeutics, Aspen Neuroscience). It also faces competition from companies using iPSC/ESC-derived cell transplants (e.g., BlueRock Therapeutics, FUJIFILM Cellular Dynamics) and gene therapy companies aiming to rescue dying cells. Large pharma entities are also active in these areas through partnerships and acquisitions.